Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index

Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index

Background Reduction in glucocorticoid exposure is the primary benefit of new biologic treatments in severe asthma, but there is currently no evidence that reduction in glucocorticoid exposure corresponds to a proportionate reduction in associated toxicity. Objectives To use the validated Glucocorti...

Full description

Bibliographic Details
Main Authors: Butler, C.A (Author), Dunn, L. (Author), Heaney, L.G (Author), Honeyford, K. (Author), Jane McDowell, P. (Author), Jayne Logan, R. (Author), McGarvey, L.P.A (Author), Stone, J.H (Author), Zhang, Y. (Author)
Format: Article
Language:English
Published: European Respiratory Society 2022
Subjects:
antiasthmatic agent
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
glucocorticoid
Glucocorticoids
human
Humans
mepolizumab
monoclonal antibody
Prospective Studies
prospective study
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items